Price targets on HLS Therapeutics have widened, with the most optimistic research pointing to C$8 while more cautious views sit near C$5. This spread reflects the recent shift in analyst commentary, where some see an inflection point for growth and cash generation, while others prefer to wait for more proof in upcoming quarters. As you read on, you will see what is driving these views and how to track the evolving story around HLS Therapeutics. Stay updated as the Fair Value for HLS...

Strong Naleo uptake and Vascepa growth drive robust performance, offset by launch-related investments impacting near-term margins

HLS Therapeutics (TSE:HLS) reported second-quarter fiscal 2026 revenue growth as its cardiovascular portfolio expanded 25% year over year, led by continued gains for Vascepa and the first full quarter of sales for newly launched NILEMDO. Total revenue for the quarter ended June 30 was $14.7 million

HLS Therapeutics (TSE:HLS) reported modest first-quarter revenue growth and reaffirmed its 2026 outlook, while management highlighted early momentum for the company’s newly launched cholesterol drug NILEMDO and continued deleveraging of its balance sheet. On a conference call discussing results for

HLS Therapeutics Inc (HLTRF) reports a 2% revenue increase and strong demand for new products, despite facing increased expenses and contracting issues.

HLS Therapeutics (HLS.TO) first-quarter net loss narrowed on lower costs and higher revenue, the com

HLS Therapeutics Inc. ( TSE:HLS ) is possibly approaching a major achievement in its business, so we would like to...

HLS Therapeutics (TSE:HLS) reported fourth-quarter and full-year 2025 results on Thursday, highlighting adjusted EBITDA growth, reduced leverage, and preparations for the Canadian launch of NILEMDO as the company works to expand its cardiovascular franchise. 2025 results: adjusted EBITDA growth and

Despite revenue challenges, HLS Therapeutics Inc (HLTRF) achieved significant EBITDA growth and reduced net debt by 23% in 2025, setting the stage for future profitability.

Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly. For...